Kamada (KMDA) FCF Payout Ratio (2025 - 2026)
Kamada (KMDA) posted quarterly FCF Payout Ratio of 21.15 for Q1 2026, up 75.08% year-on-year from 12.08 in Q1 2025, and up 1939.71% on a QoQ basis from 1.15 in Q2 2025.
Kamada (KMDA) FCF Payout Ratio (2025 - 2026) Analysis & Trends
Kamada (KMDA) has reported FCF Payout Ratio for 2 consecutive years, with 21.15 the latest figure, recorded in Q1 2026.
- Quarterly FCF Payout Ratio rose 75.08% year-over-year to 21.15 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1 (changed N/A YoY) and the FY2025 annual result came in at 0.33, changed N/A from the prior year.
- FCF Payout Ratio grew to 21.15 in Q1 2026 per KMDA's latest filing, from 1.15 in the prior quarter.
- Over the last five years, FCF Payout Ratio for KMDA reached as high as 21.15 in Q1 2026 and fell as low as 1.15 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.77 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -10.50 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.40 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 21.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.15 |
| Jun 30, 2025 | -1.15 |
| Mar 31, 2025 | 12.08 |